A Study Evaluating Pertuzumab (Perjeta) Combined With Trastuzumab (Herceptin) and Standard Anthracycline-based Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced, Inflammatory, or Early-stage Breast Cancer
Status: | Active, not recruiting |
---|---|
Conditions: | Breast Cancer, Cancer |
Therapuetic Areas: | Oncology |
Healthy: | No |
Age Range: | 18 - Any |
Updated: | 2/1/2019 |
Start Date: | July 14, 2014 |
End Date: | August 18, 2020 |
A Multicenter, Multinational, Phase II Study to Evaluate Perjeta in Combination With Herceptin and Standard Neoadjuvant Anthracycline-Based Chemotherapy in Patients With HER2-Positive, Locally Advanced, Inflammatory, or Early-Stage Breast Cancer
This multicenter, non-randomized, open-label, phase 2 study is designed to evaluate the
safety and efficacy of pertuzumab (Perjeta) in combination with trastuzumab (Herceptin) and
anthracycline-based chemotherapy as neoadjuvant treatment in participants with HER2-positive
locally advanced, inflammatory, or early-stage breast cancer. Each investigator will choose a
treatment regimen (A or B) for all of their participants to follow. Treatment regimen A (for
Cohort A) will include dose-dense doxorubicin and cyclophosphamide (ddAC), followed by
paclitaxel, with pertuzumab and trastuzumab given from the start of paclitaxel. Treatment
regimen B (for Cohort B) will include 5-fluorouracil, epirubicin, and cyclophosphamide (FEC),
followed by docetaxel, with pertuzumab and trastuzumab given from the start of docetaxel.
Participants in both cohorts will subsequently undergo surgical treatment and then resume
pertuzumab and trastuzumab treatment.
safety and efficacy of pertuzumab (Perjeta) in combination with trastuzumab (Herceptin) and
anthracycline-based chemotherapy as neoadjuvant treatment in participants with HER2-positive
locally advanced, inflammatory, or early-stage breast cancer. Each investigator will choose a
treatment regimen (A or B) for all of their participants to follow. Treatment regimen A (for
Cohort A) will include dose-dense doxorubicin and cyclophosphamide (ddAC), followed by
paclitaxel, with pertuzumab and trastuzumab given from the start of paclitaxel. Treatment
regimen B (for Cohort B) will include 5-fluorouracil, epirubicin, and cyclophosphamide (FEC),
followed by docetaxel, with pertuzumab and trastuzumab given from the start of docetaxel.
Participants in both cohorts will subsequently undergo surgical treatment and then resume
pertuzumab and trastuzumab treatment.
Inclusion Criteria:
- Male and female participants with locally advanced, inflammatory, or early-stage,
unilateral, and histologically confirmed invasive breast cancer. Participants with
inflammatory breast cancer must be able to have a core needle biopsy
- Primary tumor greater than (>) 2 centimeters (cm) in diameter, or > 5 millimeters (mm)
in diameter and node-positive
- HER2-positive breast cancer confirmed by a central laboratory
- Availability of tumor tissue specimen
- Baseline LVEF greater than or equal to (>/=) 55%
- Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to
(=) 1
- At least 4 weeks since major unrelated surgery, with full recovery
- Women of childbearing potential and male participants with partners of childbearing
potential must agree to use a "highly effective" non-hormonal form of contraception or
two "effective" forms of non-hormonal contraception by the patient and/or partner.
Contraception must continue for the duration of study treatment and for at least 7
months after the last dose of study treatment
Exclusion Criteria:
- Metastatic disease (Stage IV) or bilateral breast cancer
- Participants who have had an incisional biopsy of the primary tumor or the primary
tumor excised
- Prior breast or non-breast malignancy within 5 years prior to study entry, except for
carcinoma in situ and basal cell and squamous cell carcinoma of the skin. Participants
with malignancies occurring more than 5 years prior to study entry are permitted if
curatively treated
- Any previous systemic therapy (including chemotherapy, immunotherapy, HER2 targeted
agents, and antitumor vaccines) for cancer, or radiation therapy for cancer
- Participants with a past history of ductal carcinoma in situ (DCIS) or lobular
carcinoma in situ (LCIS) are not allowed to enter the study if they have received any
systemic therapy for its treatment or radiation therapy to the ipsilateral breast
(they are allowed to enter the study if treated with surgery alone)
- High-risk participants who have received chemopreventive drugs in the past are not
allowed to enter the study
- Inadequate bone marrow, renal, or liver function
- History or evidence of cardiovascular condition
- Dyspnea at rest or other diseases that require continuous oxygen therapy
- Severe, uncontrolled systemic disease
- Participants with poorly controlled diabetes or with evidence of clinically
significant diabetic vascular complications
- Pregnancy or breast-feeding women
- Participants who received any investigational treatment within 4 weeks of study start
- Participants with known infection with human immunodeficiency virus (HIV), hepatitis B
virus, or hepatitis C virus
- Current chronic daily treatment with corticosteroids (dose >10 mg methylprednisolone
or equivalent [excluding inhaled steroids])
- Known hypersensitivity to any of the study drugs or excipients
We found this trial at
37
sites
Click here to add this to my saved trials
Cleveland Clinic Florida Cleveland Clinic Florida, located in Weston, West Palm Beach, Palm Beach Gardens...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Hackensack University Medical Center Hackensack University Medical Center, part of the Hackensack University Health Network,...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
500 University Dr
Hershey, Pennsylvania 17033
Hershey, Pennsylvania 17033
(717) 531-6955
Penn State Milton S. Hershey Medical Center Penn State Milton S. Hershey Medical Center, Penn...
Click here to add this to my saved trials
7015 A C Skinner Parkway
Jacksonville, Florida 32256
Jacksonville, Florida 32256
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
University of Wisconsin In achievement and prestige, the University of Wisconsin–Madison has long been recognized...
Click here to add this to my saved trials
340 Kennestone Hospital Boulevard
Marietta, Georgia 30060
Marietta, Georgia 30060
Click here to add this to my saved trials
Click here to add this to my saved trials
1660 Springhill Avenue
Mobile, Alabama 36604
Mobile, Alabama 36604
(251) 665-8000
University of South Alabama Mitchell Cancer Institute USA Mitchell Cancer Institute (MCI) is located in...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Memorial Sloan Kettering Cancer Center Memorial Sloan Kettering Cancer Center — the world's oldest and...
Click here to add this to my saved trials
Click here to add this to my saved trials
2900 W Queen Ln
Philadelphia, Pennsylvania 19129
Philadelphia, Pennsylvania 19129
(215) 991-8100
Drexel University College of Medicine Drexel University College of Medicine represents the consolidation of two...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
California Pacific Medical Center California Pacific Medical Center is one of the largest private, not-for-profit,...
Click here to add this to my saved trials
Click here to add this to my saved trials
Washington, District of Columbia 20007
Click here to add this to my saved trials
Washington, District of Columbia 20010
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials